ADVM实时信号 | 通过Getagraph.com最大化利润

购买 107967 min ago

@ $2.19

发出时间: 14 Feb 2024 @ 22:34

回报率: 310.50%

上一信号: Feb 13 - 05:00

上一信号: 出售

回报率: 10.05 %

Live Chart Being Loaded With Signals

Commentary (29 Apr 2024 @ 22:01):

Stats
今日成交量	61 760.00
平均成交量	311 995
市值	186.59M
EPS	$0 ( 2024-04-04 )
下一个收益日期	( $-1.300 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.770
ATR14	$0.0580 (0.65%)

Insider Trading

Date	Person	Action	Amount	type
2023-10-03	Seyedkazemi Setareh	Buy	85 000	Stock Option (Right to Buy)
2023-10-03	Soparkar Peter	Buy	130 000	Stock Option (Right to Buy)
2023-10-03	Fischer Laurent	Buy	315 000	Stock Option (Right to Buy)
2024-02-12	Seyedkazemi Setareh	Buy	400 000	Stock Option (Right to Buy)
2024-02-12	Fischer Laurent	Buy	1 104 200	Stock Option (Right to Buy)

INSIDER POWER
97.11
Last 100 transactions
Buy: 14 665 896 \| Sell: 1 551 540

音量相关性

長: -0.06 (neutral)

短: -0.12 (neutral)

Signal:(31.119) Neutral

Adverum Biotechnologies 相关性

10 最正相关
RVNC	0.965
VCNX	0.964
LYT	0.963
SBET	0.959
RSLS	0.957
HA	0.957
BCLI	0.956
FDMT	0.955
STKS	0.954
TNYA	0.953

10 最负相关
RMRM	-0.971
ACQR	-0.963
TBSA	-0.962
HERA	-0.962
NVSA	-0.961
FRSG	-0.961
LEGA	-0.96
FTPA	-0.96
GXII	-0.96
AGGR	-0.96

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Adverum Biotechnologies 相关性 - 货币/商品

0.65
( weak )

0.68
( moderate )

0.00
( neutral )

0.67
( moderate )

0.70
( moderate )

-0.50
( neutral )

Adverum Biotechnologies 财务报表

Annual	2023
营收:	$3.60M
毛利润:	$-2.04M (-56.78 %)
EPS:	$-11.62

FY	2023
营收:	$3.60M
毛利润:	$-2.04M (-56.78 %)
EPS:	$-11.62

FY	2022
营收:	$0
毛利润:	$-6.53M (0.00 %)
EPS:	$-15.57

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-1.709

Financial Reports:

No articles found.

Adverum Biotechnologies

Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.